Posted on

MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Applauds Health Canada’s Approval Of Psilocybin Compassionate Access For Patients

New York, NY, August 6, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy.

Dr. Gasser has pioneered the legal, medical use of psychedelics through clinical research and compassionate access in Switzerland. Dr Gasser has served as the President of the Swiss Medical Society for Psycholytic Therapy since 1997. Through compassionate access in Switzerland, Dr Gasser holds several individual treatment permissions to treat patients with MDMA and LSD.

Dr. Gasser and University Hospital Basel’s Dr Matthias Liechti are conducting a Phase 2 trial of LSD assisted therapy for anxiety disorders. MindMed previously acquired the exclusive license to this ongoing Phase 2 trial through its collaboration agreement with the University Hospital Basel.

MindMed’s Project Lucy intends to start a Phase 2b human efficacy trial that will focus on experiential doses of LSD to treat anxiety disorders administered by a therapist.

“Dr. Gasser is one of the leading global experts on psychedelic assisted therapy and it’s an honor for us to work together as we build Project Lucy into a world class commercial drug development program,” said MindMed Co-Founder and Co-CEO JR Rahn. “Dr Gasser’s vast experience and history treating patients as a therapist through compassionate access in Switzerland also interests the company and will have tremendous benefits to our patients.”

Dr. Gasser helped pioneer compassionate access for end of life psychedelic assisted therapy in Switzerland. This week, the Canadian health minister approved compassionate access of psilocybin assisted therapy for terminally ill patients.

Rahn added: “Health Canada’s recognition that psychedelic substances have medicinal value and potential benefit for patients is extremely encouraging for all of us in the psychedelic inspired medical space. It takes a village of dedicated government officials, scientists, therapists and entrepreneurs to make impactful change for patients, and we hope additional clinical trials will compel regulators to further allow psychedelic inspired medicines to help the millions of patients suffering from mental health and addiction.”

‍

About MindMed

Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic-inspired medicines to improve health, promote wellness and alleviate suffering. The company has initiated or is initiating studies to evaluate potential treatments to help patients with ADHD, anxiety, cluster headaches and substance abuse. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:MMQ. For more information: www.mindmed.co.

MindMed Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of Mind Medicine (MindMed) Inc. (“MindMed”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, ” Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for  Products; unforeseen safety issues resulting from the administration of  Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting  Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies  on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.

Posted on

Novamind Sponsors TheraPsil, an Advocate for the Compassionate Use of Psilocybin in Canada

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

TORONTO, ON / ACCESSWIRE / July 31, 2020 / Novamind Ventures Inc. (”Novamind”) a mental health and wellness company specialized in psychedelic-assisted psychotherapy, is pleased to announce its sponsorship of TheraPsil (the ”TheraPsil Coalition”), a British Columbia based non-profit, composed of healthcare professionals, patients and advocates that are dedicated to obtaining legal, compassionate access to psilocybin therapy for terminally-ill Canadians suffering from end-of-life distress.

The TheraPsil Coalition supports Canadians seeking compassionate use of psilocybin by assisting individuals that apply for an exemption of subsection 56(1) of the Controlled Drugs and Substances Act (CDSA) (the ”Applications”). Canadians were first granted legal access to medical cannabis in 1999 through this same exemption.

On August 4, 2020, Canada’s Minister of Health, Patty Hajdu, is expected to respond to the Applications of four Canadians battling cancer who have been assisted by the TheraPsil Coalition.

Psilocybin-assisted psychotherapy for the treatment of end-of-life distress is supported by a growing body of clinical research. A long-term follow-up study of the NYU (New York University) 2016 Psilocybin Cancer Anxiety Study documented significant reductions in anxiety, depression, hopelessness, demoralization, and death-related anxiety nearly five years after participants were treated with psilocybin. Over 70% of study participants attributed positive life changes to the psilocybin-assisted psychotherapy experience and rated it among the most personally meaningful and spiritually significant experiences of their lives.1

“Novamind proudly supports TheraPsil’s efforts to provide compassionate access to psilocybin therapy for Canadians suffering from end-of-life distress” commented Yaron Conforti, Chief Executive Officer of Novamind.

About TheraPsil

TheraPsil is a non-profit coalition of healthcare professionals, patients and advocates that was formed in 2019, in order to change the laws regarding the use of medical psilocybin for terminally-ill patients who are experiencing end-of-life distress. TheraPsil’s mission is based on four pillars: Compassionate Access, Public Education, Professional Training, and Research. For more information visit www.therapsil.ca.

About Novamind

Novamind is building a global network of clinics and retreats that are required for a regulated psychedelics industry. We provide access to safe, legal psychedelic experiences, while advancing research for psychedelic medicine. For more information visit www.novamind.ca.

1: https://journals.sagepub.com/doi/10.1177/0269881119897615

Contact Information

Novamind
Yaron Conforti, CEO and Director
T: +1 (647) 953 9512
E: contact@novamind.ca

Posted on

Why Are Psychedelics And Mining Companies Merging In Canada?

Why Are Psychedelics And Mining Companies Merging In Canada?

Since the first psychedelic companies went public in March, an array of other psychedelic start-ups followed along in a trend that can now be safely referred to as the “Psychedelic Rush.”

In the last two months, at least five different psychedelics companies announced plans to go public in Canada, including Cybin Corp., Entheon Biomedical, Novamind Ventures, Silo Wellness and Havn Life Sciences.

With the exception of Havn, each chose to go public by way of reverse take-overs with companies from the mining sector.

As was the case with the boom of cannabis in 2013, mining companies driving the junior capital markets in Canada have laid the grounds for the development of high-risk venture industries.

Today, psychedelics are taking the lead.

Psychedelics, Reverse Acquisitions And… Mining?

What seems like an unusual combination of industries is actually a run-on-the-mill event for Canadian capital markets.

Thousands of traders are getting a 90% win-rate trading options! Click Here to See How!

Richard Carleton, CEO of the Canadian Stock Exchange, explained that the Canadian small-cap space has been largely focused on early-stage mining exploration, including oil and gas.

These companies have two possible outcomes. They either find something worth drilling and raise additional capital to develop a mine, or they don’t find anything.

“And so you have basically a group of companies that have raised some money, explored a property, didn’t succeed and now the management team and the shareholders are looking for another opportunity,” Carleton said.

That’s where psychedelics come in. These companies are trying to raise money quickly, and going public through a reverse acquisition is one of the fastest ways to do it.

In a reverse takeover (RTO), a private company looking to go public will merge with a public company in order to bypass the lengthy and expensive process of an initial public offering.

Alan Friedman, Principal at Bayline Capital Partners adds that the mining companies are available, but they’re not mining companies anymore.

“Once upon a time they were mining operating companies. Today, they’re defunct. They’re just sitting there listed on the stock exchange. And they’re good vehicles to reverse other assets into.”

For Friedman, the mining sector has “hot” cycles that last about seven years.

In 2013, one of these cycles came to an end. That moment happened to coincide with the cannabis boom. Cannabis companies were looking for ways to go public and the mining, oil and gas sector had left the perfect riverbed for a high-risk, junior capital investment market.

The same thing is happening with psychedelics.

“When you see psychedelics come along in 2020, it’s the new hot, trendy business. They can raise money, but they have to go public quick,” says Friedman. “Because a lot of the money that comes in is based on the fact they go public, because those investors like to see liquidity.”

Going Public in Canada: IPOs Vs. RTOs

According to Friedman, the quickest way for a company to go public is by way of a reverse takeover, because the vehicle and the shareholders are already there.

“80% of the companies in Canada go public by way of a reverse takeover,” Carleton said. “So it’s a very well-traveled path.”

It’s also less expensive.

“It could be a good few hundred thousand bucks cheaper,” Friedman added. “And it could be a few months quicker.”

Friedman is currently working with a private psychedelics company called Mind Health, which is in the process of negotiating a reverse takeover, and plans to go public in three months.

RTOs, however, also come with their fair share of challenges.

“When you’re switching industries, the shareholders are not in any way necessarily interested in that story or in that sector. And what can happen in a number of instances is that at the first sign of any kind of buying interest, once the company has gone public, those shareholders tend to sell so that it’s almost like there’s a built-in overhang in the company’s cap table,” Carleton explained.

As a result, when the company goes public, it’s harder to see the same kind of exuberant price moves seen when companies that go public by way of an IPO.

Also, with an RTO, the new company inherits all of the liabilities associated with the former company. And of course, in the case of mining companies, there may well be environmental issues, says Carleton.

It’s crucial to do due diligence and proper research an RTO partner before committing to a deal, Friedman advised. Although — in every case — there’s risk.

Nonetheless, RTOs are the preferred method of going public for small-cap companies in the junior markets/IPOs are reserved for larger, more established players who typically go after senior equity markets.

What To Look For In An RTO Partner?

Cybin CEO Paul Glavine is currently in the process of doing a reverse takeover with a mining company called Clarmin Explorations.

Cybin achieved full support from over 60% of Clarmin’s existing shareholders, Glavine said in an email. In this case, Clarmin’s management team will step out to let Cybin’s team on the helm.

Other psychedelics companies, like Entheon Biomedical — which merged with mining company MPV Exploration — looked for added value in their partner company. CEO Timothy Ko said MPV provided more than just a means to trade their stock on the open market.

“There was no shortage of interested, I guess, ‘shell’ partners. I think Canada has a plentitude of those opportunities available. But ultimately, it was a process of discernment where we had to say, ‘okay, the nature of the investor and the management on the other side, do they have a strategic value to us?'” says Ko.

Entheon found that MPV’s investors could add value to the company by bringing in their shared experiences in biotech, pharma and healthcare, and the management team could offer its experience raising money in the public markets.

Picture based on photos by Photo by Dominik Vanyi and Егор Камелев on Unsplash.

Posted on

Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness

Numinus provides tailored treatments for clients of one of Canada’s largest addiction treatment organizations

VANCOUVER, BC, July 29, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce its partnership with Together We Can Addiction Recovery and Education Society (TWC). TWC is one of Canada’s largest addiction treatment organizations, a registered charity, licensed healthcare provider, and an approved Canadian Federal Government service provider for the veterans’ community. The partnership has enabled TWC to enhance its mental health and addiction recovery support services with tailored mind/body wellness programs. Numinus’s associated wellness clinic is benefitting from the partnership with a dedicated stream of revenue, reinitiated since the clinic’s re-opening post-COVID earlier this month. The active service provider partnership is designed to ultimately support psychedelic-assisted therapies when authorized for use in Canada.

One in five Canadians suffer from addiction in any given year, and deaths from the current overdose crisis attributable to opioid and other addictions are growing. Numinus and TWC share the view that new solutions and integrative approaches are needed to enhance traditional recovery-based approaches to help people make transformative change, heal, and be well. The partnership currently extends the continuum of care provided to TWC clients with specialized mind/body programs which include modalities such as naturopathy, registered massage therapy, trauma and somatic therapies, and breathwork through Numinus’s associated wellness clinic in Vancouver. Individualized programs are continually being developed for TWC clients, including Canadian Forces members and veterans dealing with addiction, PTSD, anxiety, grief and loss, and other diagnoses.

Says Brett S., a TWC client who has already benefited from the partnership, “While I was in treatment at Together We Can for my drug addiction, I was given the opportunity to try out the services of the clinic. They not only supported me through recovery from my addictions but also helped me address my ADHD. I’m so grateful that Numinus’s services were part of my overall recovery.”

Longer term, the partnership also aims to provide TWC clients early-access to safe, evidence-based, regulated psychedelic-assisted therapies through Numinus’s implementation science partnerships and to provide Numinus with a key partner when it is able to provide these therapies in addition to its current services.

Although psychedelic-assisted therapies are not yet available outside of a research context, both parties are optimistic these therapies hold great promise as new treatment options for addiction and mental health care and that they will become increasingly accessible through regulatory approvals. A growing body of evidence suggests psychedelics, especially psilocybin, may dramatically improve outcomes from substance use disorders. While more research is required to fully define the outcomes and safety of the therapeutic use of psychedelic substances, the Canadian federal government is under increasing pressure to provide access to psilocybin-assisted therapy for various mental health and addiction conditions.

“The partnership with Numinus is so important for our clients. There is more demand than we can manage for our services, and our clients need the complementary programs Numinus provides,” says Stacy Wilson, TWC Executive Director. “We are excited to find a partner that is aligned with our mission and to work with a team that is driven by heartfelt passion. We both believe whole body/mind integrated support is critical to recovery, and we are optimistic that psychedelic-assisted therapies will also play a significant role in addressing addiction recovery when they are regulated.”

Adds Numinus Chief Medical Officer, Dr. Evan Wood, an internationally recognized clinician scientist and expert in addiction treatment, “The growing body of research into the role of psychedelic-assisted therapy in the treatment of substance use disorders is incredibly compelling. This partnership creates a wonderful opportunity to consolidate new strategies with an implementation science lens that can ultimately improve safe access to those seeking additional strategies for treatment and recovery.”

About Numinus
Numinus is a Vancouver-based health care company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies. Numinus’s ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit is undertaking distinct, synergistic initiatives to hasten approved access to psychedelic-assisted therapy models in Canada and position Numinus as a trusted industry leader for the eventual regulated rollout of these therapies once available. Numinus Bioscience includes a 7,000 square foot research and testing laboratory as well as numerous Health Canada licenses (through its wholly-owned subsidiary Salvation Botanicals), including a cannabis testing license which provides established and growing revenue. It is also a late-stage application for cannabis processing. Additionally, the Company holds a dealer’s licence which allows it to import, export, possess, and test MDMA, psilocybin, psilocin, DMT, and mescaline, and it is the only publicly listed company in Canada to be issued a Health Canada license to produce and extract psilocybin from mushrooms for the purpose of developing proprietary extraction methods. These licences will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus R&D leverages established relationships to position the Company for partnerships to host studies, develop medical and therapeutic protocols, and influence regulatory approval. Numinus Health, with one clinic already prototyping systems for efficiency and profitability, is dedicated to delivering therapies that enhance and supplement existing options—centred around psychedelic-assisted therapies when and where regulated—for people wanting lasting physical, mental, and emotional health. For more information, visit www.numinus.ca.

About TWC
Founded in 1993 and located in both Metro Vancouver and Vancouver Island, Together We Can – Addiction Recovery & Education Society is one of Canada’s premier treatment centres for men battling alcohol and drug addiction. Its mission is to educate and support individuals and their families who desire a new life in recovery. It provides over 310 individuals with an immersive 60-90 day recovery-based primary addiction treatment experience, followed by transitional housing in a therapeutic residential environment. For more information, visit www.twcrecoverylife.org.

Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

SOURCE Numinus Wellness Inc.

For further information: Dana Harvey, VP Communications and Investor Relations, Numinus, dana@numinus.ca, 778-929-3262; Daniel Maceachern, Operations Manager, TWC, dmaceachern@twcrecoverylife.org, (604) 451-9854

Posted on

Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4,050,000

VANCOUVER, BC, July 28, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus“) in connection with its previously announced best-efforts offering of up to 15,000,000 units the “Units“) at a price of $0.27 per Unit for gross proceeds of up to $4,050,000 (the “Offering“) in the offering jurisdictions of British Columbia, Alberta and Ontario. Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant (each whole such warrant, a “Warrant“). Each Warrant will entitle the holder to purchase one additional common share of the Company at a price of $0.40 per common share for a period of two years from issuance.

As previously disclosed, Mackie Research Capital Corporation (the “Agent“) has agreed to act as lead agent and sole bookrunner, on a best efforts basis, in respect of the Offering. The Company has granted the Agent an option (the “Agent’s Option“) exercisable by delivering a written notice of its exercise of part or all of the Agent’s Option to the Company at any time up to 48 hours prior to Closing (the “Closing“) to increase the size of the Offering by up to 15% in Units.

The Prospectus contains important information relating to the Offering and is still subject to completion or amendment. For more information, potential investors should read the Prospectus, which is available on the Company’s SEDAR profile at www.sedar.com. There will not be any sale or acceptance of an offer to buy the Units until a receipt for a final Prospectus has been issued.

The Offering is expected to close on or about August 14, 2020 and is subject to certain conditions including, but not limited to, the execution of a formal agency agreement and the receipt of all necessary regulatory approvals including the approval of the TSX Venture Exchange (the “TSXV“). The Company intends to use the net proceeds of the Offering for MDMA and psilocybin Compassionate Access protocol implementation, to make these drugs accessible to specific patient groups before they are available on the market, as more particularly described in the Prospectus. Additional funds will be used to secure therapy space and develop psychedelic integrative treatment models, support upgrades to its Lab infrastructure to support its Health Canada licences, and for general operating expenses, as more particularly described in the Prospectus.

The Company will use commercially reasonable efforts to cause the common shares forming part of the Units and the common shares underlying the Warrants to be listed on the TSXV, subject to the Company fulfilling all of the listing requirements of the TSXV.

About Numinus
Numinus is a Vancouver-based health care company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies. Numinus’s ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit is undertaking distinct, synergistic initiatives to hasten approved access to psychedelic-assisted therapy models in Canada and position Numinus as a trusted industry leader for the eventual regulated rollout of these therapies once available. Numinus Bioscience includes a 7,000 square foot research and testing laboratory as well as numerous Health Canada licenses (through its wholly owned subsidiary Salvation Botanicals), including a cannabis testing license which provides established and growing revenue. It is also a late-stage application for cannabis processing. Additionally, the Company holds a dealer’s licence which allows it to import, export, possess, and test MDMA, psilocybin, psilocin, DMT, and mescaline, and it is the only publicly listed company in Canada to be issued a Health Canada license to produce and extract psilocybin from mushrooms for the purpose of developing proprietary extraction methods. These licences will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus R&D leverages established relationships to position the Company for partnerships to host studies, develop medical and therapeutic protocols, and influence regulatory approval. Numinus Health, with one clinic already prototyping systems for efficiency and profitability, is dedicated to delivering therapies that enhance and supplement existing options—centred around psychedelic-assisted therapies when and where regulated—for people wanting lasting physical, mental, and emotional health. For more information, visit www.numinus.ca.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Offering. This news release contains “forward–looking statements“ within the meaning of Canadian securities legislation. Forward–looking statements include, but are not limited to, statements with respect to the closing of the Offering and the expected use of proceeds of the Offering. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its subsidiaries, their securities, or their respective financial or operating results (as applicable).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ON BEHALF OF THE BOARD OF NUMINUS WELLNESS INC.

Payton Nyquvest
President, Chief Executive Officer and Chair

Further information about the Company is available under its profile on the SEDAR website, www.sedar.com, and on the Company’s website.

SOURCE Numinus Wellness Inc.

For further information: Stacey Wallin, Chief Strategy Officer, 1.833.686.4687

Posted on

Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4.05 Million

Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centred on developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies, is pleased to announce it has entered into an engagement letter with Mackie Research Capital Corporation (the “Agent” or “Mackie“) in connection with a best-efforts offering of up to 15,000,000 units (the “Units“) at a price of $0.27 per Unit for gross proceeds of up to $4,050,000 (the “Offering“) in the offering jurisdictions of British Columbia, Alberta and Ontario. Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant (each whole such warrant, a “Warrant“). Each Warrant will entitle the holder to purchase one additional common share of the Company at a price of $0.40 per common share for a period of two years from issuance. The Company will grant the Agent an option (the “Agent’s Option”) exercisable at any time up to and including the closing of the Offering (the “Closing”) to increase the size of the Offering by up to 15% by giving written notice of the exercise of the Agent’s Option, or a part thereof, to the Company at any time up to 48 hours prior to Closing.

The Company intends to use the net proceeds of the Offering for MDMA and psilocybin Compassionate Access protocol implementation to make these drugs accessible to specific patient groups before they are available on the market. As per Health Canada’s Special Access Programme for Drugs Guidance Document, “where possible, open label or compassionate access trials should be incorporated into drug development plans to meet the needs of patients not eligible for enrollment in other pivotal trials.” Additional funds will be used to secure therapy space and develop psychedelic integrative treatment models, support upgrades to its Lab infrastructure to support its Health Canada licences and for general operating expenses.

Mackie has agreed to act as lead agent and sole bookrunner for the Offering on a best efforts basis and may invite other registered investment dealers to participate as syndicate members on the Offering as may be determined to the mutual satisfaction of the Agent and the Company.

In connection with the Offering the Company has agreed to pay the Agent a cash fee of 6% of the aggregate gross proceeds raised from the Offering, and issue compensation options (the “Compensation Options“) exercisable at any time up to two years following Closing to purchase broker units (the “Broker Units“) of the Company in an amount equal to 6% of the number of Units sold in connection with the Offering. The Compensation Options will be exercisable at the price of $0.27 per Broker Unit. Each Broker Unit will be comprised of one common share and one-half of one broker warrant (the “Broker Warrant“). Each Broker Warrant will be exercisable into one common share at a price of $0.40 for two years from issuance. In addition, the Company will pay Mackie a cash fee for advisory services provided in an amount equal to 2% of the gross proceeds of the Offering and will issue to Mackie advisory options having the same terms as the Compensation Options in an amount equal to 2% of the Units sold in connection with the Offering.

The Offering will be made by way of a short form prospectus (the “Prospectus“), which will be filed with the securities commissions in the Provinces of British Columbia, Alberta and Ontario. The Prospectus will contain important information about the Offering and will be available on the SEDAR website maintained by the Canadian Securities Administrators at www.sedar.com, under the Company’s profile. Any distributions of securities will only be made pursuant to the Prospectus, which remains subject to the issuance of a final receipt by the applicable securities regulators, and any other necessary regulatory approvals, including the acceptance of the TSX Venture Exchange.

About Numinus
Numinus is a Vancouver-based health care company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies. Numinus’s ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit is undertaking distinct, synergistic initiatives to hasten approved access to psychedelic-assisted therapy models in Canada and position Numinus as a trusted industry leader for the eventual regulated rollout of these therapies once available. Numinus Bioscience includes a 7,000 square foot research and testing laboratory as well as numerous Health Canada licenses (through its wholly-owned subsidiary Salvation Botanicals), including a cannabis testing license used for sustainable revenue to support the company’s psychedelic efforts. It is also a late-stage application for cannabis processing. Additionally, the Company holds a dealer’s licence which allows it to import, export, possess, and test MDMA, psilocybin, psilocin, DMT, and mescaline, and it is the only publicly listed company in Canada to be issued a Health Canada license to produce and extract psilocybin from mushrooms for the purpose of developing proprietary extraction methods. These licences will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus R&D leverages established relationships to position the Company for partnerships to host studies, develop medical and therapeutic protocols, and influence regulatory approval. Numinus Health, with one clinic already prototyping systems for efficiency and profitability, is dedicated to delivering therapies that enhance and supplement existing options—centred around psychedelic-assisted therapies when and where regulated—for people wanting lasting physical, mental, and emotional health. For more information, visit www.numinus.ca.

Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the Offering. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its subsidiaries, their securities, or their respective financial or operating results (as applicable).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ON BEHALF OF THE BOARD OF NUMINUS WELLNESS INC.

Payton Nyquvest
President, Chief Executive Officer and Chair

Further information about the Company is available under its profile on the SEDAR website, www.sedar.com, and on the Company’s website.

SOURCE Numinus Wellness Inc.

For further information: Stacey Wallin, Chief Strategy Officer, 1.833.686.4687

Posted on

Novamind Announces Closing of Oversubscribed Private Placement

Not for distribution to U.S. newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

TORONTO, ON / ACCESSWIRE / July 14, 2020 / Novamind Ventures Inc. (”Novamind” or the ”Company”), a mental health and wellness company specialized in Psychedelic-Assisted Psychotherapy (PAP), is pleased to announce that it has closed an oversubscribed private placement (the ”Financing”) raising aggregate gross proceeds of CAN$4.4 million, upsized from an original CAN$3.0 million target.

The proceeds of the Financing will support investments in Novamind’s growing, global network of clinics and retreats offering legal, medically supervised psychedelic experiences, as well as providing capital for Novamind’s pipeline of targeted investments, with additional announcements expected during July 2020.

Yaron Conforti, Chief Executive Officer and Director of Novamind commented: “We are grateful for the support from new and existing shareholders that share our vision for a new standard in mental healthcare.”

Novamind’s acquisition and investment strategy began in 2019 with an investment in the Synthesis Institute, a legal psilocybin retreat in the Netherlands (see news release dated November 18, 2019). Novamind later announced the acquisition of Utah-based Cedar Psychiatry LLC, a specialized provider of Ketamine-Assisted Psychotherapy (KAP), and Cedar Clinical Research LLC, a dedicated research center leading clinical trials for psychedelic medicines (see news release dated March 24, 2020).

Novamind’s acquisition and investment strategy is expected to continue throughout 2020, with a capital allocation plan focused on: i) KAP clinic expansion; ii) offshore retreat facility expansion; iii) clinical trials & IP; iv) developing proprietary technology.

Leveraging its early investments, and partnering with leading clinicians in the psychedelic space, Novamind is building a global network of clinics and retreats offering people access to safe, legal psychedelic experiences while advancing research for psychedelic medicine.

About Novamind

Novamind is building a global network of clinics and retreats that are required for a regulated psychedelics industry. We provide access to safe, legal psychedelic experiences, while advancing research for psychedelic medicine. For more information visit www.novamind.ca.

Contact Information

Yaron Conforti
CEO and director
T: +1 (647) 953 9512
E: info@novamind.ca

Posted on

Wuhan General Group Signs Collaborative Partnership LOI With Jugular for CBD Functional Foods

MONTREAL, QC / ACCESSWIRE / July 1, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective June 30th, 2020, it has signed a letter of intent to pursue a Partnership where Jugular will support and offer its expertise to the Company in creating a specialized division within MJ Medtech that focuses on marketable innovation within the functional foods sector.

Functional Food is defined as any modified food that claims to improve health or well-being by providing benefits beyond that of the traditional nutrients it contains.

It is anticipated that the letter of intent will be replaced with a formal agreement governing the Partnership on or before September 30, 2020. The Parties will define their collaboration for the development and manufacturing of CBD Functional Foods immediately under the Dr. AnnaRx brand:

Immune Booster Shot: The pandemic has caused a significantly heightened awareness for immune-boosting supplements that are easily ingested. Special African medicinal roots and herbs are used in combination to create this very powerful immune booster tonic.

Energy Booster Shot: Quick energy on the go. The ultimate coffee powered CBD infused shot to get added energy into your system and amplify mental clarity quickly and effectively.

Relax and Unwind Shot: This powerful formulation of Rooibos, CBD, and 8 other African medicinal herbs will help relieve many of the tensions built up during the day enabling you to enjoy a most peaceful sleep.

“Jack and I have spent immeasurable hours over the past few years discussing food science and how we might see a fit in bringing the brains behind our organizations together. We are thrilled to make this a reality and to be working with a group that cares as much about the science as we do” said Jeff Robinson, Chief Executive Officer of Wuhan General Group.

Jack Napier, Jugular Director added: “Jeff and his team at M2BIO are putting everything in place to create the right moment to bring cannabinoid-based nutraceuticals to the mass market. Jugular in partnership with M2BIO will use its extensive experience in the functional foods retail sector to unlock a new area of global profitability in the fast-growing wellness industry. We are thrilled to begin this partnership as we see the enormous potential of creating marketable innovations in this untapped new field within functional nutrition.”

About Jugular

Jugular is an innovation partner within the wellness sector, implementing our skills to bring new functional food & nutraceutical products from concept to market. Jugular comprises a cross-specialized team of wellness professionals and scientists that are passionate about making a positive impact on the world by advocating a healthy lifestyle through innovative products that are good for you. We own multiple functional food brands that are sold throughout Europe and distributed Internationally.

??Our Vision

?We seek to develop groundbreaking products incorporating new & novel ingredients into the wellness sector.

?Our Mission

?To help as many people as possible get access to advanced nutritional products. To educate, inform and break down the stigma surrounding novel foods.

?Our Strategy

?Jugular brings cutting edge new products from the concept phase through the critical path to launch. We provide expertise in sourcing, designing, manufacturing, logistics & marketing over a broad array of products including:

  • Functional Foods & RTE (Ready to Eat)
  • Ready to Drink shots and bottles
  • Powder supplements
  • Capsules, softgel and hard form nutraceuticals

We help producers and innovators of new novel ingredients find their way to the mainstream & the profitability that comes with it. Our team will guide our partners along the often-tricky path to project completion in good time.

We take fresh ideas and put them into as many hands as possible. Using market trends analysis, we determine when and how to strike with the new products that take the world by storm.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC Pink:WUHN)
Website: www.wuhn.org
E-mail:info@wuhn.org
Follow us on Twitter: https://twitter.com/WGG_Company
Follow us on Facebook: http://www.facebook.com/wuhn

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/595912/Wuhan-General-Group-Signs-Collaborative-Partnership-LOI-With-Jugular-for-CBD-Functional-Foods

Posted on

Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe

MONTREAL, QC / ACCESSWIRE / June 24, 2020, / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective June 22nd, 2020, it has entered into a manufacturing, distribution and sales agreement with Cafféluxe for an initial two-year term.

Under the terms of this agreement, Cafféluxe will manufacture Wuhan’s Medspresso™ CBD and Mushroom infused coffee, tea and hot chocolate beverages under GMP (Good Manufacturing Practices) certification. This enables Wuhan to have world-class quality products produced at the highest of safety standards ensuring remarkable customer experience.

The licensing agreement grants Cafféluxe the right to access the Medspresso™ products portfolio, including the use of the trade name, trademarks, logos and art, rights to product formulations, methods and processes. The agreement will facilitate the expansion of the Company’s Medspresso™ brand and position the Company for local (South Africa) and international distribution.

In addition to this, through the sales and distribution agreement, Cafféluxe will sell and distribute Medspresso™ products through their already established network of retailers and distributors locally and globally. Cafféluxe has demonstrated a proven ability to commercialize hot and cold beverages into the African, European, South American and North American marketplace, a key piece of the Wuhan strategic expansion plan.

The Cafféluxe agreement will enable Wuhan to enter legal, international markets around the globe, and to develop a centralized distribution channel for its suite of functional foods and wellness products.

“This partnership is a great first step in developing and executing upon a much larger strategy between Wuhan and the Cafféluxe team. We are looking forward to getting our products on the shelf as soon as the lockdown restrictions are lifted in South Africa and the supply chain constraints have been mitigated,” said Jeff Robinson, Chief Executive Officer of Wuhan General Group.

Michel Sachar, Caffeluxe Commercial Director added: “It has been a real pleasure in getting to know the Wuhan team and planning out a domestic and international launch strategy. Working with the very bright innovative minds at Wuhan has made the relationship such a delight.”

About Cafféluxe

Cafféluxe Food Service offers a full, tailored solution for the manufacturing of single-serve capsules for the retail and business to business sectors. With an in-depth understanding of the nature of coffee and a wealth of experience in the capsule manufacturing field, Cafféluxe expertly manages the process from bean to capsule to cup. This process includes granulating, filling, hermetically sealing, nitrogen flushing, QC testing, packing and branding of the capsules and machines. Cafféluxe Food Serve is able to cater for large and small orders on our machines, this allows for flexibility on various products and customer requirements. Service, compatibility, flexibility, personalization, quality assurance and competitive rates are what make Cafféluxe a leading bespoke capsule manufacturer. Since inception in 2009, Cafféluxe has patented numerous capsule designs, all modified to ensure compatibility, and continues to evolve in a competitive landscape. We provide the capsule with effective, high quality, adaptable products for small- and large-scale private label clients.

We prioritize product innovation and high-quality coffee and capsules, while simultaneously establishing and ensuring lasting relationships with our customers.

Our factory has been granted ISO Standard FSSC 22000 and HACCP Food Safe certification, as well as being FDA compliant and Halaal and Kosher certified. The capsules are subject to a variety of inline and post-production tests. This ensures the quality of the taste and functionality of capsules.

The stringent testing guarantees that Cafféluxe consistently produces capsules of the highest quality in terms of taste and functionality, and provides customers with high quality, premium products.

Profile:https://wuhn.org/wp-content/uploads/2020/06/180525-Caffeluxe-Company-Profile.pdf

Website: https://caffeluxe.com/

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC PINK:WUHN)
Website: www.wuhn.org
E-mail:info@wuhn.org
Follow us on Twitter: https://twitter.com/WGG_Company
Follow us on Facebook: http://www.facebook.com/wuhn

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

View source version on accesswire.com:
https://www.accesswire.com/595012/Wuhan-General-Group-Signs-Manufacturing-Distribution-and-Sales-Agreement-with-Caffluxe

Posted on

Numinus announces Clinical Advisory Council to advance integrated wellness model

Advisors including Dr. Gabor Maté and Zach Walsh bring training and expertise in psychedelic-assisted therapy and mental health treatment

VANCOUVER (June 24, 2020) – Numinus Wellness Inc. (“Numinus”; TSX-V: NUMI) is pleased to announce its Clinical Advisory Council, chaired by Numinus Chief Medical Officer Dr. Evan Wood. Leveraging the expertise of its members, the council will be responsible for program development, knowledge mobilization and driving policy change in the psychedelic assisted therapy space.

“Our Clinical Advisory Council brings together scientific, mental health and clinical leaders to explore the potential of psychedelic assisted therapies in a safe, controlled therapeutic environment,” says Dr. Wood. “The council will work with company leadership to drive Numinus forward and engage policy makers and legislators to create the conditions where psychedelic therapies can be considered and advanced.”

Joining Dr. Wood as initial members of the Clinical Advisory Council are recognized leaders in research and healthcare, including:

  • Dr. Gabor Maté, Retired Physician and Bestselling Author: Dr. Maté is a mental health and addiction specialist and retired physician who, after 20 years of family practice and palliative care experience, worked for over a decade in Vancouver’s Downtown Eastside with patients challenged by drug addiction and mental illness. Dr. Maté is a bestselling author who has pioneered therapies and innovative, trauma-based approaches to mental health, earning him widespread recognition from the healthcare community. drgabormate.com
  • Dr. Pam Kryskow, Physician and Clinical Instructor, University of British Columbia: Dr. Kryskow is trained in ketamine-assisted psychotherapy, chronic pain management, family medicine, rural emergency medicine and Functional Medicine. She practices medicine in British Columbia and is a clinical instructor in the Department of Medicine at the University of British Columbia. Dr. Kryskow is currently working with other university experts on research related to ketamine-assisted psychotherapy, psychedelic microdosing, MDMA for chronic pain, psilocybin and psychedelic therapy. She is actively involved with colleagues bringing scientific education around psychedelic medicines to the forefront. med.ubc.ca
  • Dr. Devon Christie, Medical Director, Numinus: Dr. Christie is a family physician with a focused practice in Multidisciplinary Pain Management and a Registered Therapeutic Counsellor, emphasizing Relational Somatic Therapy for trauma resolution. She is trained to deliver MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy in a research setting. Dr. Christie is certified in Functional Medicine, Mindfulness-Based Stress Reduction, Interpersonal Mindfulness and Kundalini Yoga. She is a recognized speaker and expert on the potential of incorporating psychedelic-assisted therapies in an integrated healthcare model and is a teacher in the postgraduate ‘Certificate in Psychedelic-Assisted Therapies and Research’ program at the California Institute of Integral Studies (CIIS).
  • Zach Walsh, Associate Professor of Psychology, University of British Columbia: Walsh is a clinical psychologist and Research Affiliate with the BC Centre on Substance Use. As an associate professor of psychology at the University of British Columbia, he directs the Therapeutic, Recreational, and Problematic Substance Use lab. Walsh has published and presented widely on topics related to psychedelics, cannabis, mental health and psychotherapy. He is an investigator for several ongoing studies of the therapeutic use of psychedelics and has worked clinically on trials of psychedelic-assisted psychotherapy. psych.ubc.ca
  • Kate Browning, Registered Nurse and Administrator & Instructor, Holistic Health, Langara College: Browning is a registered nurse specialized in mental health and substance use, psychotherapist, somatic therapist specialized in trauma and attachment, educator and doctoral candidate in clinical psychology. She was trained in ketamine-assisted psychotherapy at the Orenda Institute and with the Center for Transformational Psychotherapy. Browning has worked in a variety of healthcare and educational settings for over 25 years as a clinician, clinical supervisor, consultant, educator and lecturer and is currently an administrator and instructor in Continuing Studies with Langara College’s Holistic Health division. She is a former licensed and registered midwife with extensive training in subtle energy and consciousness-based healing practices. langara.ca
  • Dr. Jason Marr, Founder & Director, Evoke Integrative Medicine Ltd.: Marr is a naturopathic doctor, performance and productivity coach and a health and wellness speaker. His evidence-informed, holistic and integrative approach helps professionals and corporate leadership teams overcome fatigue, anxiety and burnout while maximizing performance, productivity and resilience. evokemedicine.com

 

The Clinical Advisory Council will provide guidance and support on regulatory change, program design and protocol development. Members will leverage connections in the healthcare community to collaborate with leading researchers and groups working in mental illness, addiction and trauma treatment as well as provide their unique lenses of expertise on due diligence for clinic acquisitions and Numinus’s planned flagship wellness centre. The council adds strength to Numinus’s integrative approach to driving accessibility of psychedelic-assisted therapies for all.

“We’re proud to be working with the members of our Clinical Advisory Council to find new approaches to supplement existing treatment options for mental health, addiction and trauma,” says Numinus CEO Payton Nyquvest. “Their expertise will be vital as we work with health officials, leading research organizations, medical and therapeutic governing bodies and others to create an environment where psychedelic-assisted therapies can be made available as part of our healthcare system.”

Advisory Council Members

numinus.ca/team

 

-30-

Contact:

Investor Inquiries:

invest@numinus.ca

Media Inquiries:

Emily Edwards, NATIONAL

eedwards@national.ca

604-842-6490

General Inquiries:

hello@numinus.ca

1-833-NUM-INUS (1-833-686-4687)

Pour investir et obtenir des renseignements généraux en français:

Remy Scalabrini, Maricom

investir@numinus.ca

888-585-6274

About Numinus

Numinus is a Vancouver-based health care company helping to support the universal desire to heal and be well. Through its wholly-owned subsidiary Salvation Botanicals, Numinus has a Health Canada cannabis testing licence that allows the Company to test and analyze cannabis products from licensed producers. In addition, it is a late-stage applicant to receive a Health Canada standard processing licence to produce cannabis products. Numinus, through the same subsidiary, also has a dealer’s licence which allows the Company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline, as well as produce and extract psilocybin from mushrooms. The Health Canada license also allows import/export, testing and R&D of these substances. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus Wellness is dedicated to therapies that enhance and supplement existing options for people wanting lasting physical, mental and emotional health — with psychedelic treatments at its core when approved for therapeutic and research use. Psychedelics will be part of this offering but will only be available for treatment once approved by regulators and governing bodies — a process Numinus is helping to support. For more information, visit www.numinus.ca.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.